Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252653 · ClinicalTrials.gov registry record
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
A clinical trial of Familial Amyloidotic Cardiomyopathy (FAC), sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- 1,010
- Enrollment target
- 20
- Study locations
NCT02252653: Completed study of Familial Amyloidotic Cardiomyopathy (FAC), sponsored by Alnylam Pharmaceuticals.
NCT02252653 is a study of Familial Amyloidotic Cardiomyopathy (FAC) that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,010 participants. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02252653, a study of Familial Amyloidotic Cardiomyopathy (FAC), has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- 1,010 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
Primary Outcome
Blood will be sequenced for the presence of TTR gene mutations
Conditions Studied
Study Locations (20)
California
- Clinical Trial Site - Bakersfield
- Clinical Trial Site - La Mesa
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - San Francisco
- Clinical Trial Site - Torrance
Georgia
- Clinical Trial Site - Athens
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Macon
District of Columbia
- Clinical Trial Site - Washington D.C.
- Clinical Trial Site - Washington D.C.
- Clinical Trial Site - Washington D.C.
Illinois
- Clinical Trial Site - Chicago
- Clinical Trial Site - Chicago
- Clinical Trial Site - Chicago
Arkansas
- Clinical Trial Site - Little Rock
Colorado
- Clinical Trial Site - Aurora
Florida
- Clinical Trial Site - Tampa
Indiana
- Clinical Trial Site - Merrillville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
What the finished NCT02252653 record still lists
NCT02252653 is an observational study that tracks outcomes without assigning an intervention. Its 1,010 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Familial Amyloidotic Cardiomyopathy (FAC) appearing as the primary indexed condition, and to 0 interventions.
NCT02252653 names 20 study sites across 8 states, led by California, Georgia, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02252653 about?
NCT02252653 is a clinical study titled "DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis". The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
What is the current status of trial NCT02252653?
This trial is currently completed. The enrollment target is 1,010 participants. The study started on 2014-06. Estimated completion is 2016-03.
What conditions does trial NCT02252653 study?
This clinical trial studies the following conditions: Familial Amyloidotic Cardiomyopathy (FAC).
Who is sponsoring clinical trial NCT02252653?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02252653 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia